Research
Hormonal
GLP-1 agonists reduce cardiovascular risk and all-cause mortality in diabetic populations, offering a secondary benefit for OSA patients who have high cardiometabolic risk.
For OSA patients with diabetes or high heart disease risk, GLP-1 agonists provide dual benefits: improving sleep apnea and reducing long-term cardiovascular mortality.
StrongSupportsVERY_HIGH confidence
This is of particular interest given that GLP-1 agonists reduce cardiovascular risk and all-cause mortality in diabetic populations.
Why this rating
Cited as a systematic review and meta-analysis of cardiovascular outcome trials (Ref 7).
Source
The potential impact of <scp>GLP</scp>‐1 agonists on obstructive sleep apnoea
Garun S. Hamilton et al. · Respirology · 2023
narrative_reviewCited 13×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →